MY179276A - Galectin-3 plasmapheresis therapy - Google Patents

Galectin-3 plasmapheresis therapy

Info

Publication number
MY179276A
MY179276A MYPI2016002208A MYPI2016002208A MY179276A MY 179276 A MY179276 A MY 179276A MY PI2016002208 A MYPI2016002208 A MY PI2016002208A MY PI2016002208 A MYPI2016002208 A MY PI2016002208A MY 179276 A MY179276 A MY 179276A
Authority
MY
Malaysia
Prior art keywords
gal
removal
combined
binding agents
galectin
Prior art date
Application number
MYPI2016002208A
Inventor
Eliaz Isaac
Original Assignee
Eliaz Isaac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eliaz Isaac filed Critical Eliaz Isaac
Publication of MY179276A publication Critical patent/MY179276A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
MYPI2016002208A 2013-01-07 2013-12-27 Galectin-3 plasmapheresis therapy MY179276A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361749517P 2013-01-07 2013-01-07

Publications (1)

Publication Number Publication Date
MY179276A true MY179276A (en) 2020-11-03

Family

ID=50114430

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2016002208A MY179276A (en) 2013-01-07 2013-12-27 Galectin-3 plasmapheresis therapy
MYPI2015001648A MY168406A (en) 2013-01-07 2013-12-27 Galectin-3 plasmapheresis therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2015001648A MY168406A (en) 2013-01-07 2013-12-27 Galectin-3 plasmapheresis therapy

Country Status (6)

Country Link
EP (1) EP2941284A1 (en)
AU (2) AU2013371859B2 (en)
CA (1) CA2893690A1 (en)
IL (1) IL239448A0 (en)
MY (2) MY179276A (en)
WO (1) WO2014106803A1 (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625212A (en) 1969-07-09 1971-12-07 North American Biolog Inc Eliminating mistakes in plasmapheresis
US4531932A (en) 1981-11-27 1985-07-30 Dideco S.P.A. Centrifugal plasmapheresis device
US6245038B1 (en) 1997-01-07 2001-06-12 Helmut Borberg Method for treatment of ophthalmological diseases
US6627151B1 (en) 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
US20020159995A1 (en) * 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US6462029B1 (en) 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
US6274566B1 (en) 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
CN1674955A (en) 2002-08-13 2005-09-28 阿尔比奥技术公司 Selective plasma exchange therapy
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
WO2010065765A2 (en) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
MY179044A (en) * 2011-12-08 2020-10-26 Eliaz Isaac Reduction of galectin-3 levels by plasmapheresis

Also Published As

Publication number Publication date
AU2016262697A1 (en) 2016-12-15
EP2941284A1 (en) 2015-11-11
IL239448A0 (en) 2015-07-30
WO2014106803A1 (en) 2014-07-10
AU2013371859B2 (en) 2018-06-21
MY168406A (en) 2018-11-07
CA2893690A1 (en) 2014-07-10
AU2016262697B2 (en) 2018-06-28
AU2013371859A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
MY179044A (en) Reduction of galectin-3 levels by plasmapheresis
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
WO2016025635A3 (en) Combination therapy for treating cancer
MX2016007351A (en) Combination therapy for treating cancer.
AU2012229123A8 (en) Methods of treating breast cancer with anthracycline therapy
MX2015012922A (en) Cancer treatment using antibodies that bing cell surface grp78.
WO2013082440A3 (en) Methods of treating breast cancer with taxane therapy
MX2019008085A (en) Activin-actrii antagonists and uses for treating bone and other disorders.
MX2017001138A (en) Method.
MX2015011670A (en) Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies.
EA201301354A1 (en) SGLT-2 INHIBITORS DESIGNED FOR THE TREATMENT OF METABOLIC DISORDERS IN PATIENTS TREATED BY NEUROLEPTICS
MX2016005294A (en) Methods of treating and preventing graft versus host disease.
MX2015016100A (en) Cryopyrin inhibitors for preventing and treating inflammation.
AR099707A1 (en) COMPOSITIONS AND METHODS TO TREAT RENAL DISORDERS
MX2018007823A (en) Bromodomain and extra-terminal protein inhibitor combination therapy.
MX2015011671A (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis.
MX2018000052A (en) Compositions and methods for combination therapy with dengue virus and dendritic cells.
MX2016006955A (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease.
WO2013185048A3 (en) Heterocyclic guanidine f1f0-atpase inhibitors
IL275517A (en) Methods and combination therapy to treat cancer
PH12018501790A1 (en) Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
WO2012135814A3 (en) Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
WO2012135817A3 (en) Microrna 130a,b as a tumor suppressor and sensitizing agent for chemotherapy
WO2016106357A8 (en) Combination of raf inhibitors and aurora kinase inhibitors